Skip to content
OpenCapital
Get started

Bausch Health Companies BHC Bausch + Lomb — R&D

Other segment segments

Salix
$19M+11.8%
Solta Medical
$8M+60.0%
International
$6M0.0%
Diversified
$3M0.0%

Similar metrics at other companies

Thermo Fisher Scientific logo
TMOLaboratory Products and Biopharma Services — Research and development expenses
$15M+15.4%
Thermo Fisher Scientific logo
TMOLife Sciences Solutions — Research and development expenses
$131M-5.8%
Ashland logo
ASHLife Sciences — Research And Development Expense
$3M-25.0%
Vaxcyte, Inc. logo
PCVXReportable Segment — R&D
$256.43M+147%
Immunovant, Inc. logo
IMVTReportable Segment — R&D
$29.22M-6.2%
Amneal Pharmaceuticals, Inc. logo
AMRXSpecialty — Research And Development Expense
$5.1M-43.7%

Other financials

Income statement

See full
Revenue$2.5B+11.7%
Operating income-$950.0M-444%
Net income-$1.4B-2,353%
EPS (diluted)-$3.82-2,287%

Balance sheet

See full
Cash & equivalents$1.3B+13.4%
Total debt$20.8B-3.5%
Total equity-$2.1B-74.0%
Total assets$24.5B-7.3%

Cash flow

See full
Operating cash flow$230.0M+9.0%
CapEx$109.0M-5.2%
Free cash flow$121.0M+26.0%

Valuation

See full
Market cap$1.86B-15.9%

Profitability

See full
Gross margin71.4%—
Operating margin5.6%-10.3pp
Net margin-1.9%-0.9pp
FCF margin9.8%-2.8pp

Returns & leverage

See full
Return on equity-70.1%—
Debt / equity45.2×—
Current ratio1.3×0.0×

Where this comes from

Reported directly by Bausch Health Companies in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Bausch Health Companies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch Health Companies's bausch + lomb — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch Health Companies's bausch + lomb — R&D?
Bausch Health Companies (BHC) reported bausch + lomb — R&D of $45M in Q1 2026.
How has Bausch Health Companies's bausch + lomb — R&D changed year-over-year?
Bausch Health Companies's bausch + lomb — R&D increased by 60.7% year-over-year, from $28M to $45M.
What is the long-term trend for Bausch Health Companies's bausch + lomb — R&D?
Over 3 years (2022 to 2025), Bausch Health Companies's bausch + lomb — R&D has grown at a 5.4% compound annual growth rate (CAGR), from $123M to $144M.
What does bausch + lomb — R&D mean?
Tracks the investment in scientific research and product development activities specifically for the Bausch + Lomb segment. This metric serves as a proxy for the segment's commitment to innovation and its future pipeline of new medical products.